- $1.53bn
- $1.53bn
- $2.07m
U.S. STOCKS ON THE MOVE-Stitch Fix, Tesla, Fastly, Delta Air Lines
Cyclerion Therapeutics jumps as CEO raises stake
U.S. STOCKS ON THE MOVE-Biogen, Broadcom, GM, gold miners
U.S. STOCKS ON THE MOVE-Tesla, Tapestry, Comstock, Broadcom
U.S. STOCKS ON THE MOVE-Comstock, DocuSign, Adial, The9
Cyclerion Therapeutics: Up on licensing deal for kidney disease drug
Brief: Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics For Praliciguat
Brief: Cyclerion Therapeutics Announces $18 Mln Private Placement
Brief: Cyclerion Therapeutics Announces Publication Of Cy6463 Preclinical Data In Frontiers In Pharmacology
Brief: Aavantibio Appoints Christopher Wright As Chief Medical Officer
Brief: Cyclerion Therapeutics Reports Full Year 2020 Financial Results And Corporate Update
Brief: Cyclerion Therapeutics - Preliminary Unaudited Cash, Cash Equivalents And Restricted Cash Balance As Of Dec 31, 2021 Was About $58 Million
Brief: Cyclerion Therapeutics- Announced Promotions Of Cheryl Gault To Chief Operating Officer And Anjeza Gjino To Chief Financial Officer
Brief: Cyclerion Anticipates That Its Current Cash Will Be Sufficient To Fund Its Current CNS Priorities
U.S. RESEARCH ROUNDUP-Netflix, Proteostasis Therapeutics, Zoom Video Communications
NASDAQ RESUMED AT 09:36 AM
Brief: Cyclerion Announces Positive Data From IW-6463 CNS Translational Pharmacology Study In Healthy Elderly Subjects
Brief: Cyclerion Reports Study Results In Patients With Sickle Cell Disease
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:58 AM